Rehabilitation Science, Universidade Federal de Minas Gerais and Centro Universitário de Belo Horizonte, Belo Horizonte, MG, Brazil.
Arch Phys Med Rehabil. 2013 Apr;94(4):660-6. doi: 10.1016/j.apmr.2012.11.013. Epub 2012 Nov 17.
To examine the impact of a muscle resistance program (MRP) on muscular and functional performance and on interleukin 6 (IL-6) and soluble tumor necrosis factor receptor-1 (sTNFr1) plasma levels in prefrail community-dwelling women.
Randomized controlled trial crossover design with a postintervention and short-term follow-up.
University hospital.
Prefrail community-dwelling women (N=32; ≥65y).
The MRP was designed based on the exercise at 75% of each participant's maximum load (10wk, 3 times/wk).
Plasma concentrations of IL-6 and sTNFr1 (high-sensitivity enzyme-linked immunosorbent assay kits), muscle strength of the knee extensors (isokinetic), and functional performance (Timed Up & Go [TUG] test and 10-meter walk test [10MWT]).
There were significant differences in functional and muscular performance between the pre-MRP, post-MRP, and 10-week follow-up period. After the MRP, both functional (TUG, pre-MRP=11.1s vs post-MRP=10.4s, P=.00; 10MWT, pre-MRP=4.9s vs post-MRP, 4.4s, P=.00) and muscular performances (pre-MRP=77.8% and post-MRP=83.1%, P=.02) improved. After cessation of the MRP (follow-up period), sTNFr1 plasma levels increased by 21.4% at 10-week follow-up (post-MRP, 406.4pg/mL; 10-week follow-up, 517.0pg/mL; P=.03). There were significant differences in sTNFr1 (P=.01).
The MRP was effective in improving functional and muscular performances, although alterations in plasma levels of IL-6 and sTNFr1 could not be identified after the MRP. Cessation of the MRP after 10 weeks resulted in increased plasma levels of sTNFr1.
研究肌肉抵抗计划(MRP)对虚弱前期社区居住女性肌肉功能和表现以及白细胞介素 6(IL-6)和可溶性肿瘤坏死因子受体 1(sTNFr1)血浆水平的影响。
随机对照试验交叉设计,干预后和短期随访。
大学医院。
虚弱前期社区居住女性(N=32;≥65 岁)。
MRP 基于每位参与者最大负荷的 75%(10 周,每周 3 次)设计。
IL-6 和 sTNFr1 血浆浓度(高敏酶联免疫吸附测定试剂盒)、膝关节伸肌肌力(等速)和功能表现(起立-行走测试[TUG]和 10 米步行测试[10MWT])。
在 MRP 前、后和 10 周随访期间,功能和肌肉表现存在显著差异。MRP 后,功能表现(TUG,MRP 前=11.1s,MRP 后=10.4s,P=.00;10MWT,MRP 前=4.9s,MRP 后=4.4s,P=.00)和肌肉表现(MRP 前=77.8%,MRP 后=83.1%,P=.02)均有所改善。MRP 停止后(随访期),sTNFr1 血浆水平在 10 周随访时增加了 21.4%(MRP 后,406.4pg/mL;10 周随访时,517.0pg/mL;P=.03)。sTNFr1 有显著差异(P=.01)。
MRP 有效改善了功能和肌肉表现,但在 MRP 后无法确定 IL-6 和 sTNFr1 血浆水平的变化。10 周后停止 MRP 导致 sTNFr1 血浆水平升高。